Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comfort Systems USA Inc (FIX) vs GSK plc (GSK) Price & Performance

Comfort Systems USA IncTrade

Price performance (Past 24H)

Key statistics

Comfort Systems USA Inc vs GSK plc — how do they compare? Comfort Systems USA Inc trades at $1,723 (market cap $60.06B), while GSK plc trades at $46.65 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and GSK plc for 93 Days on average.

FIXGSK
Market Cap
$60.06B$91.88B
Volume
371,8967,730,529
Sector
IndustrialsHealth
52-Week High
$2.07K$61.18
52-Week Low
$790.72$43.24
Typical Hold Time
41 Days93 Days
Enterprise Value
$58.53B$111.88B
Dividend Yield
0.21%3.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comfort Systems USA Inc

Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages and support at $1,712. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $12.53 vs. $10.45, while revenue growth accelerates from $9.1B in 2025 to $11.2B in 2026. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.

FIX presents a compelling growth opportunity with 55.56% analyst buy ratings and a $2,080 consensus price target offering 19% upside. Key risks include execution challenges in integrating acquisitions and potential margin pressure from rising costs. The stock's premium valuation (P/E 42) requires sustained earnings growth, but strong ROE (55.29%) and expanding data center backlog support the bullish case.

GSK plc

GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.

GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIX
51% Buy49% Sell
Avg holding period · 41 Days
GSK

No sentiment data available yet.

Top news

Latest headlines on both assets

About Comfort Systems USA Inc

Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.

Read more on FIX →

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK →